Skip to main content
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2018 Feb 14;21(3):513–519. doi: 10.3233/CBM-170234

Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway

Benxia Yu a,1, Wei Gao a,1, Hui Zhou b, Xia Miao c, Yuan Chang b, Liping Wang a,*, Miao Xu c, Guangzhen Ni c
PMCID: PMC13078298  PMID: 29103019

Abstract

BACKGROUND AND OBJECTIVE:

Propofol, an intravenous anesthetic agent, has been found to inhibit growth of breast cancer cells. However, the mechanisms underlying the antitumor are not known. A recent report has found that propofol could significantly downregulate miR-24 expression in the human malignant cancers. In breast cancer cells, overexpression of miR-24 promotes cell proliferation and inhibits cell apoptosis by downregulation of p27. The miR-24 has been reported to be overexpressed in breast cancer and breast cancer cell lines. In the present study, we hypothesized that propofol induces apoptosis of breast cancer cells by miR-24/p27 signal pathway.

METHODS:

Breast cancer MDA-MB-435 cells were exposed to propofol (10 μM) for 6 hr and cell death was assessed using TUNEL staining, Flow cytometry and cleaved caspase-3 expression. microRNA-24 (miR-24) expression was assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). miR-24 was overexpressed using a miR-24 mimic. P27 was knocked down using a small interfering RNA. p27 and cleaved caspase-3 expression was assessed by Western blot.

RESULTS:

MDA-MB-435 exposed to propofol showed a significant increase in apoptotic cells, followed by the downregulation of miR-24, upregulation of p27 expression and cleaved caspase-3 expression. Targeting p27 inhibits propofol-induced cell apoptosis; miR-24 overexpression decreased propofol-induced cell apoptosis, cleaved caspase-3 and p27 expression.

CONCLUSIONS:

Propofol inducescell death in MDA-MB-435 cells via inactivation of miR-24/p27 signal pathway.

Keywords: Propofol, breast cancer, miR-24, p27

1. Introduction

Propofol is widely used in all kinds of surgeries due to its short effect and rapid recovery. Apart from its multiple anesthetic advantages, propofol exerts a number of non-anesthetic effects [1]. In HL-60 human promyelocytic leukemia cells, propofol was shown to inhibit growth and induce the formation of apoptotic bodies, increase DNA fragmentation and laddering, activate caspase-3, caspase-6, caspase-8 and caspase-9, and induce the cytosolic release of cytochrome c [2]. In pancreatic cancer PANC-1 cells, propofol inhibited cell growth and invasion, and induced apoptosis, in a dose- and time-dependent manner [3]. In lung cancer cells, propofol statistically decreased cell viability but increased the percentages of apoptotic cells by activation of FOXO1, FOXO3, Bim, and pro- and activated caspases-3; however, miR-486 inhibitor reversed the effects of propofol on cell viability, apoptosis, and protein expression [4]. In breast cancer, propofol plays a important role of inhibiting the invasion and migration of breast cancer cells in the therapy of chronic breast cancer patients [5]. Deegan et al. has found that serum from patients receiving propofol/paravertebral anaesthesia for breast cancer surgery inhibited proliferation, but not migration, of ER-MDA-MB-231 cells in vitro [6]. Therefore, it would be of great importance to investigate the relationship between propofol and cancer.

MicroRNAs (miRNAs) are emerging as robust players of gene regulation. Numerous miRNAs have been implicated in a variety of cellular processes including differentiation, cell proliferation, apoptosis, embryonic development, stress response, stem cell renewal and metabolism [7, 8, 9, 10, 11]. miRNAs have also been implicated to play important roles in inducing apoptosis [12, 13, 14]. However, the effect of miRs on anesthetic-induced apoptosis in breast cancer cells has yet to be studied.

Recent studies have shown that miR-24 is upregulated in highly differentiated CD8+ T cells upon etoposide treatment and associated with a decreased DNA damage response [15] and in oral squamous cell carcinomas (OSCC) as compared to their matched controls [16], as well as in hepatocellular carcinomas (HCC), its expression being higher in higher grade HCC [17]. Moreover, miR-24 is overexpressed in glioblastomas and promotes cell growth and migration in glioma cells both in vitro and in vivo [18]. In addition, miR-24 can inhibit apoptosis of both cancer cells [19] and cardiomyocytes [20] and can accelerate cell proliferation [21]. Upregulation of miR-24 has been observed in oral carcinoma [22] and is one of the most abundant miRNAs in cervical cancer [23]. Giglio et al. has reported that miR-24 directly targets p27(Kip1) in primary keratinocyte and in different cancer derived cell lines promoting their proliferation, suggesting that miR-24 is involved in cyclin-dependent kinase inhibitors post-transcriptional regulation [24]. Recently, it has found that miR-24 was downregulated following exposure to propofol, we hypothesized that the miR-24 signaling pathway (miR-24/p27) plays a role in the increased cell death observed in the breast cancer cells following propofol.

2. Materials and methods

2.1. Cell culture

MDA-MB-435 cells (ATCC, Shanghai, China) were cultured in DMEM supplemented with 10% FCS, 2 mM L-Glutamine, 100 Units/ml Penicillin and100 μg/ml Streptomycin (Gibco, Life Technologies, Carlsbad, CA, US). Cell lines were grown at 37C, 5% CO2.

2.2. Propofol exposure

Pure propofol (2, 6-diisopropylphenol) was obtained from AstraZeneca, and the intralipid (20% emulsion, phospholipid-stabilized soybean oil) was obtained from Sigma-Aldrich. MDA-MB-435 cells were cultured in 96-well plates (2 × 104 per well) and treated with 10 μM propofol for 6 h. After washing, cells were then cultured in DMEM supplemented with 10% FBS and antibiotics for another 24 h. To determine the role of proof-induced apoptosis, cell viability and involved signaling pathways, cells were transfected with miR-24 mimics or p27 siRNA or control siRNA 6 h before the addition of propofol.

2.3. qRT-PCR assay

Total miRNA was isolated through the mirVana miRNA isolation kit (Ambion). Quantitative expression studies of miR24 transcripts were performed using TaqMan miRNA Assays (Applied Biosystem). The cDNA was obtained using the High Capacity RNA-to-cDNA Kit (Applied Biosystem). cDNA was amplified using specific primer for miR-24 (Applied Biosystem). qRT-PCR was performed using an Applied Biosystems 7900HT Fast RT-PCR system. The expression level of miR-24 was calculated according to the 2-ΔΔCt method, using the GAPDH gene as an internal control. All reactions were performed in triplicate.

2.4. Western blot analysis

The primary antibodies used were mouse anti-p27, rabbit anti-cleaved caspase-3, and mouse anti-GAPDH. The horseradish peroxidase-conjugated secondary antibody (1:5000; Santa Cruz Biotechnology) and chemiluminescence Supersignal (Pierce) was used to detect protein. Protein loading was normalized for GAPDH signal. Band intensity was quantified versus a control sample (considered as 1).

2.5. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining

The cell arrays were fixed with 3.7% formaldehyde for 20 min at room temperature. After two PBS washes, the permeabilization was performed with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min at room temperature. After washing with PBS, the appropriate volume of freshly prepared TUNEL reaction mixture (In Situ Cell Death Detection Kit, Fluorescein, Roche) was added to the slides and the slides were incubated in a humid atmosphere for 60 min at 37C in the dark. After three PBS washes, the cell arrays were mounted for fluorescence microscopy or a scanner analysis. Alternatively, AlexaFluor 488-conjugated anti-Fluorescein/Oregon Green goat antibody (Molecular Probes) was used as a secondary antibody to amplify the fluorescence signal while still allowing fluorescein-compatible optics. TUNEL positive nuclei were quantified blinded for 5 fields per slide using a fluorescence microscope (Zeiss Axioplan2 fluorescence microscope).

2.6. Flow cytometric analysis of cell apoptosis

Apoptosis assay was performed using Vybrant Apo- ptosis Assay kit (Invitrogen) according to manufacturer’s instructions. Both apoptotic cells (PI- Annexin V+) and necrotic and late apoptotic cells (PI+ Annexin V+) were counted.

2.7. Statistical analysis

The data were expressed as the means ± SD. Statistical analysis was performed using the two-tailed and paired Student’s t test. P< 0.05 was considered statistically significant and indicated by an asterisk.

3. Results

3.1. Propofol induces cell death of MDA-MB-435 cells

The TUNEL-positive cells was 1.04% ± 0.69% in untreated MDA-MB-435 cells. After exposure to 10 uM propofol for 6 h hours, the number of TUNEL-positive cells (15.4% ± 3.8%) was significantly inc- reased compared to PBS-treated cells following 10 uM propofol for 6 hours (1.7% ± 0.72%) (Fig. 1A, p< 0.01). Apoptosis (annexin V/PI) analysis was performed using flow cytometry. The apoptosis rate of the MDA-MB-435 cells was analyzed using CellQuest software. The apoptosis rates of the propofol-treated cells were 31.2% ± 4.7%, which is significantly increased compared to PBS-treated cells (2.6% ± 1.04%) (Fig. 1B, p< 0.01). No differences were observed between the untreated cells and the PBS-treated cells (Fig. 1B).

Figure 1.

Figure 1.

Propofol increases cell apoptosis in the propofol-treated cells. A, Imaging of cell apoptosis determined by TUNEL assay. Nuclei of apoptosis was identified as TUNEL positive (green fluorescent) cell. Scale bar represents 50 um (p< 0.01). B, Cells apoptosis induced by propofol was analyzed using the annexin V (FITC)/PI binding assay by flow cytometry. The values are the means (± SE) of three independent experiments. Statistical analysis was performed by comparing the annexin V and PI indexes in cells that were treated with propofol with those in cells of untreated and intralipid groups (p*< 0.01).

3.2. Propofol downregulates miR-24 and induces apoptosis in MDA-MB-435 cells

We first investigated the effects of propofol on miR-24 expression of MDA-MB-435 cells. Exposure to 10 uM propofol for 6 hours in MDA-MB-435 cells led to rapid miR-24 downregulation (Fig. 2A). However, transient miR-24 mimics transfection reveresd propofol-induced miR-24 downregulation (Fig. 2A) and reduced apoptosis following propofol treatment (Fig. 2B and C). Taken together, these data suggest that propofol decreased miR-24 expression, resulting in the induction of apoptosis in the MDA-MB-435 cells.

Figure 2.

Figure 2.

Downregulation of miR-24 is required for the apoptotic activity of propofol. MDA-MB-435 cells were transiently transfected with miR-24 mimics or control miR or/and treated with 10 uM propofol for 6 h. A, miR-24 expression was detected by qRT-PCR assay; B, Imaging of cell apoptosis determined by TUNEL assay. Nuclei of apoptosis was identified as TUNEL positive (green fluorescent); C, Cells apoptosis induced by propofol was analyzed using the annexin V (FITC)/PI binding assay by flow cytometry (p*< 0.01).

3.3. MiR-24-dependent induction of p27 by propofol

We then determined whether propofol-induced miR-24-dependent p27 expression. Exposure to 10 uM propofol for 6 hours in led to P27 upregulation (Fig. 3). However, transient miR-24 mimics transfection aggravated propofol-induced P27 upregulation (Fig. 3), suggesting that p27 was miR-24 negatively dependent regulation.

Figure 3.

Figure 3.

Propofol directly mediates miR-24/P27 induction. Cells were transfected with miR-24 mimics and/or treated with 10 uM propofol for 6 h. P27, caspase-3 and cleaved-caspase-3 was detected by western blot assay.

Caspases family plays an important role to regulate cell apoptosis, the mechanisms of which involved in the upstream initiators and downstream effectors. For example, caspase-3 is a main caspase effector. Therefore, we detected the effect of propofol on activity of caspase-3. As seen in Fig. 3, propofol significantly increased the caspase-3 activity by western blot assay. However, transient miR-24 mimics transfection inhibited propofol-induced caspase-3 upregulation and activation (Fig. 3).

3.4. P27 mediates propofol-induced apoptosis

We then investigate the role of P27 in propofol-induced apoptosis. Exposure to 10 μM propofol for 6 hours in MDA-MB-435 cells triggered P27 expression and caspase-3 cleavage (Fig. 3). Targeting p27 by P27 siRNA transfection inhibited P27 expression and caspase-3 activation (Fig. 4A), followed by the decreased of cell apoptosis induced by propofol (Fig. 4B and C).

Figure 4.

Figure 4.

P27 mediates propofol-induced apoptosis. Cells were transfected with P27 siRNA and/or treated with 10 μM propofol for 6 h. A, P27, caspase-3 and cleaved-caspase-3 were detected by western blot assay. B, Imaging of cell apoptosis determined by TUNEL assay. Nuclei of apoptosis was identified as TUNEL positive (green fluorescent) (p*< 0.01). C, Cells apoptosis induced by propofol was analyzed using the annexin V (FITC)/PI binding assay by flow cytometry (p*< 0.01).

4. Discussion

Previous studies on proof have mainly focused on its clinical effects and side effects [25, 26, 27] and some investigations have indicated that propofol could induce neurotoxicity [28]. A recent study showed that propofol can induce cancer cell apoptosis [29, 30, 31]. Studies have shown that propofol could induce tumor cell apoptosis by downregulation of miRs, such as miR-34a-5p [32], miR-4295 [33], miR-222 [34], miR-574–3p [35] and miR-9 [36]. However, the detailed mechanism about how miRs induces apoptosis is not clear. Studies have shown that miRs induce tumor cell apoptosis via regulation of p27 expression [37, 38, 39]. Lynch et al. has reported that miR-24 has a tumor suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells [40]. However, miR-24 inhibits apoptosis in human breast cancer by targeting p27 [41, 42, 43]. miR-24 was found to be significantly decreased in the human embryonic stem cell-derived neurons induced by propofol and significantly induced cell death [44, 45]. Therefore, we explored whether propofol could control miR-24/P27 pathway to induce apoptosis in breast cancer cells.

In our study, miR-24 was significantly downregulated in MDA-MB-435 cells when exposure to 10 uM propofol for 6 hours followed by increasing cell death. However, overexpression of miR-24 by miR-24 mimics transfection in MDA-MB-435 cells significantly decreased toxic effects of propofol, suggesting that miR-24 plays an important role in resistance of MDA-MB-435 cells cell death.

miRNAs-mediated control is one of the posttranscriptional mechanisms responsible for p27 downregulation in cancer cells. p27 posttranslational regulation is mediated by multiple phosphoacceptor sites, controlling both nucleo-cytoplasmic shuttling and stability of the protein [46]. Reduced expression of p27 is frequently observed in various cancers [47, 48, 49] and correlates with poor prognosis [50, 51]. From these studies, it is clear that p27 is a promising target for tumor therapies. In fact, it is reported that overexpression of p27 suppresses tumor growth in various cancers [49, 52]. The role of miR-24 in regulating the expression of p27 and regulation of cell survival is well-established [41, 42, 43, 44, 45].

In the present study, we found that miR-24 was significantly downregulated and p27 and cleaved caspase-3 were significantly upregulated following exposure to 10 μM propofol for 6 hours. However, overexpression of miR-24 by miR-24 mimics transfection in MDA-MB-435 cells significantly inhibited propofol-induced p27 and cleaved caspase-3 expression. In addition, targeting P27 by siRNA transfection inhibited propofol induced cell death and caspase-3 activation, suggesting that miR-24/P27 pathway is contributing to the propofol-induced cell death.

Some limitations are avaliable in the current study. First of all, we only used one cell line MDA-MB-435 at present. More breast cancer cell lines will be included in our following study. Secondly, MDA-MB-435 cells were treated with 10 μM propofol for 6 h. In the future, we will test the effect of propofol on apoptosis at various concentrations and for various durations of treatment. Thirdly, propofol induced apoptosis of MDA-MB-435 cells by miR-24/p27 signal at present. Whether other miRs or p16 are associated with the regulation of propofol need further investigation in the following study.

In conclusion, propofol induces cell death in breast cancer cells via inactivation of miR-24 and activation of p27 signal pathway. miR-24 in propofol-induced cell apoptosis could possibly pave the way for new research into possible strategie for treatment of breast cancer.

Conflict of interest

No.

References

  • [1]. Vasileiou I., Xanthos T., Koudouna E., Perrea D., Klonaris C., Katsargyris A. and Papadimitriou L., Propofol: A review of its non-anaesthetic effects, Eur J Pharmacol 605(1–3) (2009), 1–8. [DOI] [PubMed] [Google Scholar]
  • [2]. Tsuchiya M., Asada A., Arita K., Utsumi T., Yoshida T., Sato E.F., Utsumi K. and Inoue M., Induction and mechanism of apoptotic cell death by propofol in HL-60 cells, Acta Anaesthesiol Scand 46(9) (2002), 1068–1074. [DOI] [PubMed] [Google Scholar]
  • [3]. Liu Z., Zhang J., Hong G., Quan J., Zhang L. and Yu M., Propofol inhibits growth and invasion of pancreatic cancer cells through regulation of the miR-21/Slug signaling pathway, Am J Transl Res 8(10) (2016), 4120–4133. [PMC free article] [PubMed] [Google Scholar]
  • [4]. Yang N., Liang Y., Yang P., Yang T. and Jiang L., Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression, Braz J Med Biol Res 50(1) (2017), e5794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5]. Li Q., Zhang L., Han Y., Jiang Z. and Wang Q., Propofol reduces MMPs expression by inhibiting NF-κB activity in human MDA-MB-231 cells, Biomed Pharmacother 66(1) (2012), 52–56. [DOI] [PubMed] [Google Scholar]
  • [6]. Deegan C.A., Murray D., Doran P., Ecimovic P., Moriarty D.C. and Buggy D.J., Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro, Br J Anaesth 103(5) (2009), 685–690. [DOI] [PubMed] [Google Scholar]
  • [7]. Karp X. and Ambros V., Developmental biology, encountering microRNAs in cell fate signaling, Science 310(5752) (2005), 1288–1289. [DOI] [PubMed] [Google Scholar]
  • [8]. Chen C.Z., Li L., Lodish H.F. and Bartel D.P., MicroRNAs modulate hematopoietic lineage differentiation, Science 303(5654) (2004), 83–86. [DOI] [PubMed] [Google Scholar]
  • [9]. Stadler B.M. and Ruohola-Baker H., Small RNAs: Keeping stem cells in line, Cell 132(4) (2008), 563–566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10]. Yi R., Poy M.N., Stoffel M. and Fuchs E., A skin micro- RNA promotes differentiation by repressing ‘stemness’, Nature 452(7184) (2008), 225–229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11]. Cheng A.M., Byrom M.W., Shelton J. and Ford L.P., Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis, Nucleic Acids Res 33(4) (2005), 1290–1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12]. Liao X.H., Xiang Y., Yu C.X., Li J.P., Li H., Nie Q., Hu P., Zhou J. and Zhang T.C., STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells, Oncotarget 8(9) (2017), 15763–15774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13]. Xia W., Zhou J., Luo H., Liu Y., Peng C., Zheng W. and Ma W., MicroRNA-32 promotes cell proliferation, migration and suppresses apoptosis in breast cancer cells by targeting FBXW7, Cancer Cell Int 17 (2017), 14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14]. Fan X., Zhou S., Zheng M., Deng X., Yi Y. and Huang T., MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM), Biomed Pharmacother 88(6) (2017), 507–514. [DOI] [PubMed] [Google Scholar]
  • [15]. Brunner S., Herndler-Brandstetter D., Arnold C.R., Wiegers G.J., Villunger A., Hackl M., Grillari J., Moreno-Villanueva M., Burkle A. and Grubeck-Loebenstein B., Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8(+) T cells sensitizing them to apoptotic cell death, Aging Cell 11(8) (2012), 579–587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16]. Lin S.C., Liu C.J., Lin J.A., Chiang W.F., Hung P.S. and Chang K.W., miR-24 up-regulation in oral carcinoma: Positive association from clinical and in vitro analysis, Oral Oncology 46(11) (2010), 204–208. [DOI] [PubMed] [Google Scholar]
  • [17]. Hatziapostolou M., Polytarchou C., Aggelidou E., Drakaki A., Poultsides G.A., Jaeger S.A., Ogata H., Karin M., Struhl K., Hadzopoulou-Cladaras M. and Iliopoulos D., An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis, Cell 147(4) (2011), 1233–1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18]. Chen L., Zhang A., Li Y., Zhang K., Han L., Du W., Yan W., Li R., Wang Y., Wang K., Pu P., Jiang T., Jiang C. and Kang C., MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling, Cancer Letters 329(2) (2013), 174–180. [DOI] [PubMed] [Google Scholar]
  • [19]. Qin W., Shi Y., Zhao B., Yao C., Jin L., Ma J. and Jin Y., miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells, PLoS One 5 (2010), e9429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20]. Qian L., Van Laake L., Huang Y., Liu S., Wendland M.F. and Srivastava D., miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes, J Exp Med 208(2) (2011), 549–560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21]. Zaidi S.K., Dowdy C.R., van Wijnen A.J., Lian J.B., Raza A., Stein J.L., Croce C.M. and Stein G.S., Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network, Cancer Res 69(5) (2009), 8249–8255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22]. Lin S.C., Liu C.J., Lin J.A., Chiang W.F., Hung P.S. and Chang K.W., miR-24 up-regulation in oral carcinoma: Positive association from clinical and in vitro analysis, Oral Oncol 46(6) (2010), 204–208. [DOI] [PubMed] [Google Scholar]
  • [23]. Wang X., Tang S., Le S.Y., Lu R., Rader J.S., Meyers C. and Zheng Z.M., Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth, PLoS One 3 (2008), e2557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24]. Giglio S., Cirombella R., Amodeo R., Portaro L., Lavra L. and Vecchione A., MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a, J Cell Physiol 228(3) (2013), 2015–2023. [DOI] [PubMed] [Google Scholar]
  • [25]. Bodnar J., A review of agents for palliative sedation/contin- uous deep sedation: Pharmacology and practical applications, J Pain Palliat Care Pharmacother 31(1) (2017), 16–37. [DOI] [PubMed] [Google Scholar]
  • [26]. Peng K., Liu H.Y., Wu S.R., Liu H., Zhang Z.C. and Ji H., Does propofol anesthesia lead to less postoperative pain compared with inhalational anesthesia? A systematic review and meta-analysis, Anesth Analg 123(4) (2016), 846–858. [DOI] [PubMed] [Google Scholar]
  • [27]. Finsterer J. and Frank M., Propofol is mitochondrion-toxic and may unmask a mitochondrial disorder, J Child Neurol 31(9) (2016), 1489–1494. [DOI] [PubMed] [Google Scholar]
  • [28]. Bosnjak Z.J., Logan S., Liu Y. and Bai X., Developmental neurotoxicity: Implications for the protective strategies, Anesth Analg 123(5) (2016), 1286–1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29]. Li H., Lu Y., Pang Y., Li M., Cheng X. and Chen J., Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway, Biomed Pharmacother 86(8) (2017), 324–333. [DOI] [PubMed] [Google Scholar]
  • [30]. Xu Y.J., Li S.Y., Cheng Q., Chen W.K., Wang S.L., Ren Y. and Miao C.H., Effects of anaesthesia on proliferation, invasion and apoptosis of LoVo colon cancer cells in vitro, Anaesthesia 71(10) (2016), 147–154. [DOI] [PubMed] [Google Scholar]
  • [31]. Zhang D., Zhou X.H., Zhang J., Zhou Y.X., Ying J., Wu G.Q. and Qian J.H., Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer, Biochem Biophys Res Commun 468(4) (2015), 561–567. [DOI] [PubMed] [Google Scholar]
  • [32]. Pu Y., Zhao F., Li Y., Cui M., Wang H., Meng X. and Cai S., The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene, BMC Cancer 217 (2017), 45. [Google Scholar]
  • [33]. Nan Y.H., Wang J., Wang Y., Sun P.H., Han Y.P., Fan L., Wang K.C., Shen F.J. and Wang W.H., MiR-4295 promotes cell growth in bladder cancer by targeting BTG1, Am J Transl Res 8(10) (2016), 4892–4901. [PMC free article] [PubMed] [Google Scholar]
  • [34]. Zhou Z., Zhou L., Jiang F., Zeng B., Wei C., Zhao W. and Yu D., Downregulation of miR-222 Induces apoptosis and cellular migration in adenoid cystic carcinoma cells, Oncol Res 25(8) (2017), 207–214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35]. Xu H., Liu X., Zhou J., Chen X. and Zhao J., miR-574-3p acts as a tumor promoter in osteosarcoma by targeting SMAD4 signaling pathway, Oncol Lett 12(3) (2016), 5247–5253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36]. Huang X., Teng Y., Yang H. and Ma J., Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-κB signal, Braz J Med Biol Res 49(5) (2016), e5717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37]. Guo S.L., Zheng P., Xue Y., Fan K.J., Ye H., Li Z.H., Wang Y., Xu X.L. and Yang X., miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells, Int J Biol Sci 7(2) (2017), 567–574. [Google Scholar]
  • [38]. Oya Y., Masuzaki R., Tsugawa D., Ray K.C., Dou Y. and Karp S.J., Dicer-dependent production of microRNA221 in hepatocytes inhibits p27 and is required for liver regeneration in mice, Am J Physiol Gastrointest Liver Physiol 3(1) (2017), 41–48. [Google Scholar]
  • [39]. Wang C., Ba X., Guo Y., Sun D., Jiang H., Li W., Huang Z., Zhou G., Wu S., Zhang J. and Chen J., MicroRNA-199a-5p promotes tumour growth by dual-targeting PIAS3 and p27 in human osteosarcoma, Sci Rep 7(6) (2017), 41456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40]. Lynch S.M., McKenna M.M., Walsh C.P. and McKenna D.J., miR-24 regulates CDKN1B/p27 expression in prostate cancer, Prostate 76(4) (2016), 637–648. [DOI] [PubMed] [Google Scholar]
  • [41]. Lu K., Wang J., Song Y., Zhao S., Liu H., Tang D., Pan B., Zhao H. and Zhang Q., miRNA-24-3p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting p27Kip1, Oncol Rep 34(9) (2015), 995–1002. [DOI] [PubMed] [Google Scholar]
  • [42]. Roscigno G., Puoti I., Giordano I., Donnarumma E., Russo V., Affinito A., Adamo A., Quintavalle C., Todaro M., Vivanco M.D. and Condorelli G., MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer, Oncotarget 4(12) (2017), 176–183. [Google Scholar]
  • [43]. Giglio S., Cirombella R., Amodeo R., Portaro L., Lavra L. and Vecchione A., MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a, J Cell Physiol 228(8) (2013), 2015–2023. [DOI] [PubMed] [Google Scholar]
  • [44]. Sun W. and Pei L., microRNA expression profiling of propofol-treated developing rat hippocampal astrocytes, DNA Cell Biol 34(7) (2015), 511–523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [45]. Neudecker V., Brodsky K.S., Kreth S., Ginde A.A. and Eltzschig H.K., Emerging roles for microRNAs in perioperative medicine, Anesthesiology 124(7) (2016), 489–506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [46]. Sherr C.J. and Roberts J.M., CDK inhibitors: Positive and negative regulators of G1-phase progression, Genes Dev 13(2) (1999), 1501–1512. [DOI] [PubMed] [Google Scholar]
  • [47]. Lloyd R.V., Jin L., Qian X. and Kulig E., Aberrant p27kip1 expression in endocrine and other tumors, Am J Pathol 150(6) (1997), 401–407. [PMC free article] [PubMed] [Google Scholar]
  • [48]. Slingerland J. and Pagano M., Regulation of the cdk inhibitor p27 and its deregulation in cancer, J Cell Physiol 183(8) (2000), 10–17. [DOI] [PubMed] [Google Scholar]
  • [49]. Nickeleit I., Zender S., Kossatz U. and Malek N.P., p27kip1: A target for tumor therapies? Cell Div 2 (2007), 13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50]. Kudo Y., Kitajima S., Sato S., Miyauchi M., Ogawa I. and Takata T., High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas, Cancer Res 61(19) (2001), 7044–7047. [PubMed] [Google Scholar]
  • [51]. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M. and Giordano G.G., Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer, Cancer Res 57(16) (1997), 3381–3385. [PubMed] [Google Scholar]
  • [52]. Jiang F., Caraway N.P., Li R. and Katz R.L., RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells, Oncogene 24(21) (2005), 3409–3418. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES